Antibiotic expected effectiveness and cost under real life microbiology: evaluation of ertapenem and ceftriaxone in the treatment of community-acquired pneumonia for elderly patients in Spain

References

• NiedermanMSMcCombsJSUngerANKumarAPopovianRThe cost of treating community-acquired pneumoniaClin Ther19982048208379737840
   PubMed Web of Science ®Google Scholar
• GaribaldiRAEpidemiology of community-acquired respiratory tract infections in adults. Incidence, etiology, and impactAm J Med1985786B32374014285
   PubMed Web of Science ®Google Scholar
• Rajas NaranjoOAspa MarcoJ2004: Año de la Neumonía. Consecuencias e impacto científico en Archivos de Bronconeumología [Pneumonia awareness year, 2004: scientific impact through publications in Archivos de Bronconeumología]Arch Bronconeumol20064210541552 Spanish17067522
   PubMed Web of Science ®Google Scholar
• BayasJMVilellaASan-MartínMGonzálezAConesaAAsenjoMAImpacto Sanitario de los ingresos por neumonía en un hospital de tercer nivel [Impact of hospital admissions for pneumonia in a tertiary Spanish hospital]Med Clin (Barc)200111618694695 Spanish11412681
   PubMed Web of Science ®Google Scholar
• BlanquerJSanzFNeumonía adquirida en la comunidad [Community-acquired pneumonia]Arch Bronconeumol201046Suppl 72630 Spanish21316547
   PubMedGoogle Scholar
• MenéndezRTorresAAspaJCapelastequiAPratCRodríquez de CastroFNeumonía adquirida en la comunidad. Nueva normativa de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR) [Community-acquired pneumonia. New guidelines of the Spanish Society of Chest Disease and Thoracic Surgery (SEPAR)]Arch Bronconeumol20104610543558 Spanish20832928
   PubMed Web of Science ®Google Scholar
• BurkhardtODerendorfHWelteTErtapenem: the new carbapenem 5 years after first FDA licensing for clinical practiceExpert Opin Pharmacother20078223725617257093
   PubMed Web of Science ®Google Scholar
• EpsteinJSHasselquistSMSimonGLEfficacy of ceftriaxone in serious bacterial infectionsAntimicrob Agents Chemother19822134024066285809
   PubMed Web of Science ®Google Scholar
• MurciaJMGonzález-ComecheMarínASCAPE Study GroupClinical response to ertapenem in severe community-acquires pneumonia: a retrospective series in an elderly populationClin Microbiol Infect200915111046105019548926
   PubMed Web of Science ®Google Scholar
• Vila-CorcolesAOchoa-GondarORodriguez-BlancoTRaga-LuriaXGomez-BertomeuFEPIVAC Study GroupEpidemiology of community-acquired pneumonia in older adults: a population-based studyRespir Med2009103230931618804355
   PubMed Web of Science ®Google Scholar
• Fernández-SabéNCarratalàJRosónBCommunity-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomesMedicine (Baltimore)200382315916912792302
   PubMed Web of Science ®Google Scholar
• MandellLAWunderinkRGAnzuetoAInfectious Diseases Society of AmericaAmerican Thoracic SocietyInfectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adultsClin Infect Dis200744Suppl 2S27S7217278083
   PubMed Web of Science ®Google Scholar
• Ortiz-RuizGCaballero-LopezJFriedlandIRWoodsGLCaridesAProtocol 018 Ertapenem Community-Acquired Pneumonia Study GroupA study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adultsClin Infect Dis20023481076108311914996
   PubMed Web of Science ®Google Scholar
• VetterNCambronero-HernandezERohlfJProtocol 020 Study GroupA prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumoniaClin Ther200224111770178512501873
   PubMed Web of Science ®Google Scholar
• Ortiz-RuizGVetterNIsaacsRCaridesAWoodsGLFriedlandIErtapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studiesJ Antimicrob Chemother200453Suppl 2ii59ii6615150184
   PubMed Web of Science ®Google Scholar
• WoodsGLIsaacsRDMcCarrollKAFriedlandIRErtapenem therapy for community-acquired pneumonia in the elderlyJ Am Geriatr Soc200351111526153214687380
   PubMed Web of Science ®Google Scholar
• ArancibiaFEwigSMartinezJAAntimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implicationsAm J Respir Crit Care Med2000162115416010903235
   PubMed Web of Science ®Google Scholar
• RomanelliGCravarezzaPPozziACarbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapyJ Chemother200214660961712583553
   PubMed Web of Science ®Google Scholar
• FineMJAubleTEYealyDMA prediction rule to identify low-risk patients with community-acquired pneumoniaN Engl J Med199733642432508995086
   PubMed Web of Science ®Google Scholar
• LivermoreDMCarterMWBagelSIn vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and AustraliaAntimicrob Agents Chemother20014561860186711353638
   PubMed Web of Science ®Google Scholar
• Pérez-TralleroEMarimónJMLarruskainJAlonsoMErcibengoaMAntimicrobial susceptibilities and serotypes of Streptococcus pneumoniae isolates from elderly patients with pneumonia and acute exacerbation of chronic obstructive pulmonary diseaseAntimicrob Agents Chemother20115562729273421402843
   PubMed Web of Science ®Google Scholar
• GobernadoMSanz-RodríguezCVillanuevaRTorrobaLRedondoEGonzález-EstebanJActividad in vitro de ertapenem frente a cepas bacterianas clínicas aisladas en 69 centros médicos españoles (Estudio E-test) [In vitro activity of ertapenem against clinical bacterial isolates in 69 Spanish medical centers (E-test study)]Rev Esp Quimioter2007204395408 Spanish18563213
   PubMed Web of Science ®Google Scholar
• MarcheseAGualcoLSchitoAMDebbiaEASchitoGCIn vitro activity of ertapenem against selected respiratory pathogensJ Antimicrob Chemother200454594495115472001
   PubMed Web of Science ®Google Scholar
• JansenJPKumarRCarmeliYAccounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UKPharmacoeconomics200927121045105619908928
   PubMed Web of Science ®Google Scholar
• JansenJPKumarRCarmeliYCost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistanceValue Health200912223424420667059
   PubMed Web of Science ®Google Scholar
• MenéndezRTorresAZalacaínRNeumofail GroupRisk factors of treatment failure in community acquired pneumonia: implications for disease outcomeThorax2004591196096515516472
   PubMed Web of Science ®Google Scholar
• Hospital discharge register-(Conjunto mínimo de datos CMBD)Pestadistico.msc.es [homepage on the Internet]MadridSpanish Ministry of Health Available from: http://pestadistico.msc.es./PEMSC25/Accessed October 30, 2013
   Google Scholar
• Royal Decree-law 4/2010, May 26 [homepage on the Internet]Información orientativa sobre los factores de conversión del PVL a PVP y PVP IVA, aplicables a partir del 1 de julio de 2010MadridSpanish Ministry of Health Available from: http://www.msps.es/profesionales/farmacia/pdf/margenesFactoresConversion.pdfAccessed October 30, 2013
   Google Scholar
• Spanish General Council of Official Colleges of Pharmacists – Botplus [homepage on the Internet] Available from: https://botplusweb.portalfarma.com/Accessed October 30, 2013
   Google Scholar
• Royal Decree-law 8/2010, May 20 [homepage on the Internet]MadridSpanish Ministry of Health Available from: http://www.msps.es/profesionales/farmacia/notasInfor.htmAccessed October 30, 2013
   Google Scholar
• NightingaleCHAmbrosePFileTMJrCommunity-Acquired Respiratory Infections: Antimicrobial Management2nd edNew YorkMarcel Dekker Inc2005
   Google Scholar
• CapelasteguiAEspañaPPQuintanaJMDeclining length of hospital stay for pneumonia and postdischarge outcomesAm J Med20081211084585218823851
   PubMed Web of Science ®Google Scholar
• Garcia-VidalCCarratalàJDíazVFactores relacionados con una estancia media hospitalaria prolongada en la neumonía adquirida en la comunidad [Factors associated with prolonged hospital stay in community-acquired pneumonia]Enferm Infecc Microbiol Clin2009273160164 Spanish19306716
   PubMed Web of Science ®Google Scholar